SLC5A2 and diabetes mellitus: Dapagliflozin was the first SGLT2 inhibitor that was approved by FDA to treat diabetes mellitus, the chemical structure of which is illustrated in Fig. 1A. First, a CCK-8 experiment was conducted in HPC to assess the safety of the dapagliflozin dosage.